The Veterans Health Administration will cover Eisai and Biogen’s new Alzheimer’s drug Leqembi (lecanemab), reversing on an earlier decision to not pay for veterans to access Biogen’s other amyloid-targeted drug Aduhelm (aducanumab).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,